Reports
Sale
Global Viral Vector Vaccines Market Size, Share, Report: By Type: Adenovirus, Retrovirus, Plasmid DNA, AAV, Lentivirus, Others; By Applications: Antisense and RNAi, Gene Therapy, Cell Therapy, Vaccinology; By Disease: Cancer, Genetic Disorders, Infectious Diseases, Others; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Global Viral Vector Vaccines Market Outlook
The global viral vector vaccines market size was valued at USD 820.22 million in 2023, driven by the increasing awareness about gene therapy among government and people across the globe. The market size is anticipated to grow at a CAGR of 19.6% during the forecast period of 2024-2032 to achieve a value of USD 4,106.85 million by 2032.
Viral Vector Vaccines: Introduction
Viral vector vaccines are a type of vaccine that uses a harmless virus to deliver a piece of genetic material from a pathogen (like a virus or bacterium) into the body. This genetic material instructs cells to produce a specific part of the pathogen, usually a harmless piece called an antigen. The immune system recognizes this antigen as foreign and mounts a protective immune response, producing antibodies and memory cells.
Global Viral Vector Vaccines Market Analysis
The increasing use of gene therapy across a wide range of medical conditions, such as infectious diseases, and others including cancer, genetic disorders, and autoimmune conditions, is a major trend influencing the market growth. Viral vectors are employed in gene therapy to deliver functional genes into cells to treat genetic disorders. The genetic material can correct mutations, replace missing proteins, or modulate gene expression.
The increasing number of license approvals is significantly driving the market growth, including the recent license approval made by the FDA. The FDA has accepted Vertex Pharmaceuticals’ biologics license application (BLA) for exagamglogene autotemcel (exa-cel) for treating severe sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT). The FDA has granted priority review for SCD with a Prescription Drug User Fee Act (PDUFA) target action date of December 8, 2024, and Standard Review for TDT with a PDUFA target action date of March 30, 2024.
Viral vectors are used in gene therapy to deliver functional genes into cells to treat genetic disorders. The genetic material can correct mutations, replace missing proteins, or modulate gene expression. Increased awareness of viral vector vaccines, driven by high-profile vaccine campaigns, is positively influencing perspective of people about the utilization and benefits of viral vector vaccines, further boosting the global viral vaccines market growth.
Beacon Therapeutics is a leading ophthalmic gene therapy company launched with USD 120 million in June 2024. The investments were made by Syncona Limited and other investors, acquiring assets from a program entitled AGTC at the University of Oxford. The lead asset obtained by Beacon is AGTC-501, an investigational gene therapy intended to treat X-linked retinitis pigmentosa, which is currently being evaluated in multiple clinical trials.
Global Viral Vector Vaccines Market Segmentations
Market Breakup by Type
- Adenovirus
- Retrovirus
- Plasmid DNA
- AAV
- Lentivirus
- Others
Market Breakup by Applications
- Antisense and RNAi
- Gene Therapy
- Cell Therapy
- Vaccinology
Market Breakup by Disease
- Cancer
- Genetic Disorders
- Infectious Diseases
- Others
Market Breakup by End User
- Pharmaceutical
- Biopharmaceutical Companies
- Research Institute
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Viral Vector Vaccines Market Overview
The rising prevalence of target disease and disorders is continuously driving the market growth. The increasing awareness among people about the importance and application of gene therapy is also driving the market growth. The availability of funding for gene therapy delivery due to the investments by government and key players of the market is also contributing to the viral vector vaccines market growth.
The rising incidence of genetic disorders, cancer, HIV, tuberculosis, cardiovascular diseases, and infectious diseases are driving the market growth. The rising number of clinical trials, increasing investments towards the development of gene therapies, and potential uses for novel drug delivery systems are all collectively driving the market growth. The increasing geriatric population is also a major cause of market growth across the globe. The increasing technological advancements in the production of viral vectors is also an accountable for the global viral vector vaccines market growth. The high operational cost associated with cell and gene therapy manufacturing is expected to restrain the growth of the market.
North America is currently leading the global market due to the presence of highly advanced and equipped research labs to carry research leading to the development of viral vector vaccines. The development of novel medicines is done at a fast pace in the region with the use of viral and non-viral vectors. These vectors can deliver a gene to a specific cell or tissue in vivo. Adeno-associated virus, lentivirus, and retrovirus are examples of viral vectors used in clinical and preclinical trials to evaluate gene and cell therapy products and vaccines.
Viral Vector Vaccines Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Novasep
- Merck KGaA
- Charles River Laboratories
- uniQure N.V
- Waisman Biomanufacturing
- Creative-Biogene
- Aldevron
- Addgene
- Oxford Biomedical
- Thermo Fisher Scientific Inc
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Applications |
|
| Breakup by Disease |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Viral Vector Vaccines Market Overview
3.1 Global Viral Vector Vaccines Market Historical Value (2017-2023)
3.2 Global Viral Vector Vaccines Market Forecast Value (2024-2032)
4 Global Viral Vector Vaccines Market Landscape
4.1 Global Viral Vector Vaccines: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Viral Vector Vaccines: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Disease
4.2.3 Analysis by Applications
5 Global Viral Vector Vaccines Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Viral Vector Vaccines Market Segmentation
6.1 Global Viral Vector Vaccines Market by Type
6.1.1 Market Overview
6.1.2 Adenovirus
6.1.3 Retrovirus
6.1.4 Plasmid DNA
6.1.5 AAV
6.1.6 Lentivirus
6.1.7 Others
6.2 Global Viral Vector Vaccines Market by Applications
6.2.1 Market Overview
6.2.2 Antisense and RNAi
6.2.3 Gene Therapy
6.2.4 Cell Therapy
6.2.5 Vaccinology
6.3 Global Viral Vector Vaccines Market by Disease
6.3.1 Market Overview
6.3.2 Cancer
6.3.3 Genetic Disorders
6.3.4 Infectious Diseases
6.3.5 Others
6.4 Global Viral Vector Vaccines Market by End User
6.4.1 Market Overview
6.4.2 Pharmaceutical
6.4.3 Biopharmaceutical Companies
6.4.4 Research Institute
6.5 Global Viral Vector Vaccines Market by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Viral Vector Vaccines Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Viral Vector Vaccines Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Viral Vector Vaccines Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Viral Vector Vaccines Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Viral Vector Vaccines Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Novasep
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 Merck KGaA
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Charles River Laboratories
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 uniQure N.V
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Waisman Biomanufacturing
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Creative-Biogene
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Aldevron
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Addgene
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Oxford Biomedical
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Thermo Fisher Scientific Inc
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 820.22 million in 2023, driven by the increasing prevalence of targeted diseases.
The market is anticipated to grow at a CAGR of 19.6% during the forecast period of 2024-2032, and likely to reach a market value of USD 4,106.85 million by 2032.
The rising incidence of cancer, HIV, cardiovascular diseases, and infectious diseases are driving the market growth.
The increasing investments for research and development of viral vector vaccines is a major trend influencing the market growth.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is currently leading the global market.
The various viral vectors include adenovirus, retrovirus, plasmid DNA, AAV, lentivirus, among others.
Diseases like cancer, genetic disorders, infectious diseases, among others can be treated by the help of viral vector vaccines.
They find wide applications in antisense and RNAi, gene therapy, cell therapy, and vaccinology.
The end users in the market include pharmaceutical, biopharmaceutical companies, and research institutes.
Key players involved in the market are Novasep, Merck KGaA, Charles River Laboratories, uniQure N.V, Waisman Biomanufacturing, Creative-Biogene, Aldevron, Addgene, Oxford Biomedical, and Thermo Fisher Scientific Inc.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER